Почетна › Рак на дојка › Alabama
Клинички испитувања за Рак на дојка во Alabama
29 студии за Рак на дојка бараат учесници на локации во Alabama.
Градови во Alabama
Официјален текст на студијата (англиски)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Central Alabama Research, Birmingham
Се регрутираФаза 3
Возраст од 18 до 100 · Сите полови · Ажурирано 2.10.2026 · NCT05827081A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06760819A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 2
Возраст 60 и постари · Жени · Ажурирано 30.9.2026 · NCT06105684A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07222267A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06103864Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
Се регрутира
Возраст од 18 до 90 · Жени · Ажурирано 25.9.2026 · NCT06294574A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06618287A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 22.9.2026 · NCT07287098Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
Се регрутираДобредојдени се здрави волонтери
Возраст од 30 до 74 · Жени · Ажурирано 21.9.2026 · NCT02620852A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Southern Cancer Center, PC, Daphne
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT06492616Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 10.9.2026 · NCT06293898Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
Се регрутираНабљудувачка студија
Возраст од 18 до 99 · Сите полови · Ажурирано 3.9.2026 · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 26.8.2026 · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
Се регрутираФаза 3
Возраст од 18 до 100 · Сите полови · Ажурирано 6.8.2026 · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
Се регрутираДобредојдени се здрави волонтери
Возраст од 45 до 74 · Жени · Ажурирано 31.7.2026 · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
Се регрутираФаза 1
Возраст од 18 до 100 · Сите полови · Ажурирано 29.7.2026 · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 15.5.2026 · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 6.5.2026 · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 30.4.2026 · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
Се регрутираФаза 3
Возраст од 50 до 70 · Сите полови · Ажурирано 23.4.2026 · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 25.2.2026 · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
Се регрутираРана фаза 1
Возраст 18 и постари · Жени · Ажурирано 26.1.2026 · NCT03321045Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 20.1.2026 · NCT05693766Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- The University of Alabama at Birmingham, Birmingham
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 16.12.2025 · NCT04722341RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
Се регрутира
Возраст од 18 до 99 · Сите полови · Ажурирано 31.10.2025 · NCT03643861SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.